GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Pacific Biosciences of California (PACB) [hlAlert]

Rating:
Buy PACB
up 92.85 %

Pacific Biosciences of California (PACB) rated Buy with price target $8 by Maxim Group

Posted on: Thursday,  Sep 26, 2013  8:25 AM ET by Maxim Group

Maxim Group rated Buy Pacific Biosciences of California (NASDAQ: PACB) on 09/26/2013. Previously Maxim Group rated Buy Pacific Biosciences of California (NASDAQ: PACB)
on 01/14/2013., when the stock price was $2.52. Since then, Pacific Biosciences of California has gained 92.86% as of 01/20/2016's recent price of $4.86.
If you would have followed the previous Maxim Group's recommendation on PACB, you would have gained 92.85% of your investment in 1101 days.

Pacific Biosciences of California is development-stage company. The Company develops, manufactures and markets an integrated platform for genetic analysis. The Company has developed a technology to study the synthesis and regulation of deoxyribonucleic acid (DNA). Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, the Company created a technology platform using its single molecule, real-time (SMRT) technology. Its SMRT technology uses the natural processing power of enzymes, combined with designed reagents and detection systems, to record individual biochemical events as they occur. The Company?s initial focus is on the DNA sequencing market where it has developed and introduced a third-generation sequencing platform using its SMRT technology, the PacBio RS.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/26/2013 8:25 AM Buy
None
5.95 8.00
as of 12/13/2013
1 Week up  11.46 %
1 Month up  19.70 %
3 Months up  33.15 %
1 YTD down  -18.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/14/2013 10:25 AM Buy
None
2.52 4.00
6/21/2011 8:25 AM Hold
None
11.46

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy